Arima Genomics Partners with Active Motif to Expand Access to Hi-C Research Technologies While Accelerating Clinical Cancer Diagnostics Strategy
Arima Genomics, Inc., a biotechnology company focused on advancing precision oncology through innovative cancer diagnostics, has announced a new strategic distribution partnership with Active Motif Incorporated, a global provider of epigenetics and multiomics research solutions. The agreement grants Active Motif exclusive distribution rights for Arima’s portfolio of Hi-C research kits and services, enabling broader access to the company’s three-dimensional (3D) genomics technologies while allowing Arima to intensify its focus on developing and commercializing its clinical cancer diagnostic platform.
The partnership represents an important strategic step for both organizations. While Active Motif expands its portfolio of advanced genomic research technologies for academic, translational, and pharmaceutical researchers, Arima Genomics will concentrate its resources on advancing its proprietary clinical diagnostics that leverage chromosome conformation capture technology to improve cancer detection and therapy selection.
By separating its research products from its clinical diagnostic initiatives through an established commercialization partner, Arima aims to accelerate innovation in precision oncology while ensuring that researchers worldwide continue to benefit from its advanced genomic technologies.
Expanding Access to Advanced 3D Genomics Research Tools
Under the terms of the agreement, Active Motif will become the exclusive distributor of Arima’s comprehensive portfolio of Hi-C research kits and associated laboratory services intended for research applications.
The agreement encompasses Arima’s complete suite of three-dimensional genomics products designed for non-formalin-fixed paraffin-embedded (non-FFPE) biological samples. These include cell lines, peripheral blood samples, and fresh-frozen tissues commonly used in biomedical research laboratories around the world.
The availability of these technologies through Active Motif is expected to increase accessibility for researchers investigating genome architecture, chromatin organization, gene regulation, epigenetic mechanisms, and numerous other biological processes.
Because Active Motif already maintains an extensive global commercial network serving life science researchers, the partnership provides a well-established distribution infrastructure capable of supporting broader adoption of Arima’s technologies across academic institutions, biotechnology companies, pharmaceutical organizations, and government research laboratories.
The collaboration enables researchers to continue accessing highly specialized genomic technologies while benefiting from Active Motif’s scientific support, customer service, and existing relationships throughout the global research community.
Understanding Hi-C Technology
Hi-C technology has emerged as one of the most powerful tools for studying the three-dimensional organization of the genome.
Unlike traditional DNA sequencing methods that primarily determine the linear sequence of genetic material, Hi-C captures the physical interactions between distant regions of chromosomes, revealing how DNA is folded and organized within the cell nucleus.
This three-dimensional architecture plays a critical role in regulating gene expression, controlling cellular function, and influencing disease development.
Understanding chromosome organization provides scientists with insights that extend beyond conventional sequencing, enabling researchers to identify structural variations, chromosomal rearrangements, regulatory interactions, and higher-order genome organization that may influence both normal biology and disease processes.
Over the past decade, Hi-C has become increasingly important in fields including cancer biology, developmental biology, neuroscience, immunology, and evolutionary genomics.
The technology has also become an essential tool for constructing high-quality reference genomes and improving genome assembly for both human and non-human species.
Broad Applications Across Biomedical Research
The research products included in the distribution agreement support a wide variety of scientific applications.
One major area of application involves epigenetics, where researchers investigate how chromatin organization influences gene activity without altering the underlying DNA sequence.
Hi-C technology enables scientists to examine long-range genomic interactions that regulate gene expression and cellular identity, providing valuable insights into developmental processes and disease mechanisms.
The technology is also widely used in studies of human health and disease, where researchers seek to understand how structural alterations in chromosome organization contribute to conditions including cancer, neurological disorders, and inherited genetic diseases.
In addition, Hi-C has become increasingly valuable for generating reference-quality genome assemblies, particularly for complex genomes that require accurate chromosome-level organization.
Researchers studying biodiversity, agriculture, conservation biology, and evolutionary genetics frequently employ Hi-C data to improve genome assembly accuracy and facilitate haplotype phasing, allowing more precise characterization of genetic variation.
By making these technologies more broadly available through Active Motif, the partnership supports continued scientific discovery across numerous research disciplines.
Supporting Arima’s Clinical Strategy
While the agreement expands research access, it also aligns with Arima Genomics’ evolving corporate strategy.
The company has increasingly focused its efforts on translating its proprietary Hi-C technology into clinical diagnostic applications capable of improving cancer diagnosis and treatment selection.
Rather than continuing to divide resources between research product commercialization and clinical development, Arima will now dedicate greater attention to advancing its precision oncology platform.
The company’s clinical diagnostics are built upon proprietary Hi-C sequencing methods capable of capturing both DNA sequence information and the three-dimensional structural organization of cancer genomes.
This integrated approach allows clinicians to identify complex genomic abnormalities that may be overlooked or incompletely characterized using conventional molecular testing approaches.
By concentrating organizational resources on clinical diagnostics, Arima aims to accelerate development of technologies that can directly influence patient care.
Advancing Cancer Diagnostics Through Genome Structure
Traditional genomic testing methods primarily focus on identifying mutations within the DNA sequence itself.
However, many cancers are driven not only by sequence mutations but also by structural alterations involving chromosome rearrangements, gene fusions, inversions, translocations, and other complex genomic events.
Arima’s technology addresses this limitation by simultaneously evaluating both DNA sequence and genome structure.
The company’s proprietary Hi-C sequencing platform captures the spatial organization of chromosomes within tumor cells, enabling identification of clinically significant structural variants that conventional sequencing approaches may fail to detect or fully characterize.
This additional layer of genomic information has the potential to improve diagnostic accuracy while identifying therapeutic targets that might otherwise remain undetected.
As precision oncology increasingly depends upon comprehensive molecular characterization of tumors, technologies capable of revealing complex structural genomic alterations are becoming increasingly important.
Foundation for the Aventa Diagnostic Platform
Arima’s proprietary Hi-C technology serves as the scientific foundation for its expanding portfolio of clinical diagnostic tests.
Among these are Aventa FusionPlus, designed for patients with solid tumors, and Aventa Lymphoma, developed specifically for hematologic malignancies.
Both diagnostic assays are intended to identify actionable gene fusions, chromosomal rearrangements, and structural genomic alterations that can influence treatment selection.
Many modern targeted cancer therapies are designed to treat tumors driven by specific genetic abnormalities. Accurate identification of these biomarkers is therefore essential for matching patients with appropriate precision medicines.
By utilizing three-dimensional genomic information alongside traditional DNA sequencing, Arima’s diagnostic platform seeks to improve detection of clinically actionable alterations that conventional testing workflows may miss.
Enhanced detection capabilities could ultimately contribute to more informed therapeutic decisions and improved patient outcomes.
CEO Highlights Future Vision
Tom Willis, Ph.D., Chief Executive Officer of Arima Genomics, explained that the partnership supports the company’s long-term vision for transforming cancer diagnostics.
According to Willis, the future of precision oncology extends beyond simply reading the DNA sequence. Instead, he believes the greatest opportunity lies in combining DNA sequence information with an understanding of genome structure to reveal the underlying biological mechanisms driving cancer development.
He noted that the agreement allows Arima to focus its scientific, operational, and commercial resources on advancing its Aventa clinical diagnostic platform while ensuring continued availability of its research technologies through Active Motif’s well-established commercial infrastructure.
Willis emphasized that Active Motif’s complementary product portfolio and longstanding relationships throughout the life sciences research community make the company well positioned to support researchers utilizing Arima’s Hi-C technologies.
The collaboration enables both organizations to focus on their respective strengths while continuing to advance innovation across research and clinical applications.
Industry Perspective on Clinical Opportunity
The strategic significance of the partnership was also highlighted by Malek Faham, M.D., Ph.D., Chief Scientist at Illumina Ventures.
According to Faham, Arima has developed a highly differentiated genomic technology platform capable of fundamentally changing how clinically important genomic alterations are detected and interpreted in cancer.
He explained that concentrating resources on clinical diagnostics strengthens Arima’s ability to address limitations associated with traditional molecular testing approaches.
By focusing on clinically meaningful structural genomic alterations that may escape conventional sequencing methods, the company is positioned to generate insights that can directly influence patient management and treatment decisions.
Faham suggested that this sharpened strategic focus increases Arima’s opportunity to contribute meaningfully to the rapidly evolving field of precision oncology.
Active Motif Strengthens Multiomics Portfolio
For Active Motif, the partnership represents a significant expansion of its growing portfolio of advanced genomic and epigenomic research technologies.
The company has established itself as a leading supplier of products supporting epigenetics, chromatin biology, gene regulation, and multiomics research.
Adding Arima’s Hi-C technologies complements Active Motif’s existing offerings by enabling customers to study genome organization alongside other molecular features such as chromatin accessibility, transcription factor binding, DNA methylation, and histone modifications.
The integrated portfolio provides researchers with broader capabilities for investigating complex biological systems using multiple complementary genomic approaches.
As demand continues increasing for comprehensive multiomic analyses that integrate diverse molecular datasets, partnerships such as this help researchers access increasingly sophisticated experimental tools through a single trusted supplier.
Positioning for Future Growth
The exclusive distribution agreement reflects the evolving priorities of both organizations as the life sciences industry continues advancing toward increasingly specialized research and clinical applications.
For Arima Genomics, the collaboration creates an opportunity to accelerate development of innovative cancer diagnostics built upon its proprietary three-dimensional genomic sequencing platform. By concentrating resources on its Aventa clinical diagnostic portfolio, the company seeks to advance precision oncology through improved detection of clinically actionable genomic alterations.
For Active Motif, the addition of Arima’s Hi-C technologies enhances its position as a leading provider of epigenetics and multiomics solutions, enabling researchers worldwide to continue exploring genome organization and chromatin biology using state-of-the-art tools.
Together, the partnership supports scientific discovery while advancing the broader goal of translating increasingly sophisticated genomic technologies into improved diagnostic capabilities and more personalized treatment strategies for patients with cancer. As precision medicine continues to evolve, collaborations that bridge cutting-edge research technologies with clinical innovation are expected to play an increasingly important role in shaping the future of healthcare.
About Arima Genomics
Arima Genomics is a cancer diagnostics company redefining cancer testing by bringing DNA sequence and structure together. Built on leadership in 3D genome science and Hi-C sequencing technology, Arima develops clinical tests that reveal cancer-driving alterations conventional approaches can miss or incompletely characterize. Through its Aventa clinical testing brand, Arima offers testing for solid tumors and lymphoma from its CLIA-certified laboratory in Orlando, Florida. Learn more at www.arimagenomics.com and aventatest.com, and follow us on LinkedIn.
About Active Motif
Active Motif is a leading provider of epigenetics, genomics, and multiomics solutions that enable researchers to investigate gene regulation, chromatin biology, and disease mechanisms. Through innovative products, services, and scientific expertise, Active Motif supports researchers worldwide in advancing discoveries that improve human health.